What is the share price of Alivus Life Sciences Ltd (ALIVUS) today?
The share price of ALIVUS as on 14th November 2025 is ₹904.70. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Alivus Life Sciences Ltd (ALIVUS) share?
The past returns of Alivus Life Sciences Ltd (ALIVUS) share are- Past 1 week: -1.40%
- Past 1 month: -2.90%
- Past 3 months: -4.17%
- Past 6 months: -23.39%
- Past 1 year: -16.43%
- Past 3 years: 113.50%
- Past 5 years: 20.87%
What are the peers or stocks similar to Alivus Life Sciences Ltd (ALIVUS)?
The peers or stocks similar to Alivus Life Sciences Ltd (ALIVUS) include:What is the dividend yield % of Alivus Life Sciences Ltd (ALIVUS) share?
The current dividend yield of Alivus Life Sciences Ltd (ALIVUS) is 0.55.What is the market cap of Alivus Life Sciences Ltd (ALIVUS) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Alivus Life Sciences Ltd (ALIVUS) is ₹11098.98 Cr as of 14th November 2025.What is the 52 week high and low of Alivus Life Sciences Ltd (ALIVUS) share?
The 52-week high of Alivus Life Sciences Ltd (ALIVUS) is ₹1251 and the 52-week low is ₹850.What is the PE and PB ratio of Alivus Life Sciences Ltd (ALIVUS) stock?
The P/E (price-to-earnings) ratio of Alivus Life Sciences Ltd (ALIVUS) is 22.85. The P/B (price-to-book) ratio is 3.94.Which sector does Alivus Life Sciences Ltd (ALIVUS) belong to?
Alivus Life Sciences Ltd (ALIVUS) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy Alivus Life Sciences Ltd (ALIVUS) shares?
You can directly buy Alivus Life Sciences Ltd (ALIVUS) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Alivus Life Sciences Ltd
ALIVUS Share Price
904.700.10% (+0.90)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
ALIVUS Stock Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
GoodThe stock is underpriced and is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
ALIVUS Performance & Key Metrics
ALIVUS Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 20.93 | 3.94 | 0.55% |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 37.01 | 5.84 | 0.58% |
100%
Analysts have suggested that investors can buy this stock
from 3 analysts
Price Upside
Earnings Growth
Rev. Growth
ALIVUS Company Profile
Alivus Life Sciences Ltd develops and manufactures active pharmaceutical ingredients (APIs) and provides contract development and manufacturing services for chronic therapeutic areas.
SUNPHARMA
PE Ratio
38.57
38.57
1Y Return
0.63%
0.63%
Buy Reco %
91.43
91.43
TORNTPHARM
PE Ratio
67.85
67.85
1Y Return
23.51%
23.51%
Buy Reco %
76.92
76.92
CIPLA
PE Ratio
23.47
23.47
1Y Return
2.16%
2.16%
Buy Reco %
67.74
67.74
DRREDDY
PE Ratio
18.34
18.34
1Y Return
1.57%
1.57%
Buy Reco %
41.94
41.94
ZYDUSLIFE
PE Ratio
21.00
21.00
1Y Return
1.35%
1.35%
Buy Reco %
50.00
50.00
ALIVUS Sentiment Analysis
ALIVUS Sentiment Analysis
New
Crisp summary & key insights to decode earnings calls instantly
ALIVUS Stock Summary · August 2025
In the first quarter ending June 30, 2025, the company demonstrated modest revenue growth of 2.2%, primarily driven by its non-GPL business, while facing a significant 22% decline in the GPL segment due to inventory rationalization. Despite rising operational expenses, gross margins improved to 55.1%, reflecting enhanced efficiency. Management remains optimistic about future growth, targeting a net profit of INR 1,000 crores within five years, bolstered by a robust pipeline of high-potent APIs and significant potential in the CDMO sector. However, challenges persist in the specialty projects and generic API markets, necessitating a strategic focus on cost management and innovation to sustain long-term profitability. Overall, the sentiment reflects confidence in leveraging existing capabilities and strategic investments to drive future growth.
ALIVUS Stock Growth Drivers
ALIVUS Stock Growth Drivers
8Strong Financial Performance
Alivus Life Sciences reported revenues of INR 602 crores for the quarter ended June 30,
Successful Product Launches and Pipeline Development
The company has successfully launched new products, particularly in the non-GPL business, which saw a
ALIVUS Stock Challenges
ALIVUS Stock Challenges
4Declining Fixed Asset Turnover Ratio (FATR)
The company's Fixed Asset Turnover Ratio (FATR) has decreased from 3.4 in FY '22 to
Rising Operating Expenses
There has been a significant increase in operating expenses (opex) of 14%, while revenue growth
ALIVUS Forecast
ALIVUS Forecasts
Price
Revenue
Earnings
ALIVUS Share Price Forecast
ALIVUS Share Price Forecast
2025
Current
₹904.70
Baseline
Forecast for Nov 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹
2025
Current
₹904.70
Baseline
Forecast for Nov 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹
ALIVUS Company Revenue Forecast
ALIVUS Company Revenue Forecast
2025
Current
₹2.42
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹ Thousand cr.
2025
Current
₹2.42
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹ Thousand cr.
ALIVUS Stock EPS (Earnings Per Share) Forecast
ALIVUS Stock EPS (Earnings Per Share) Forecast
2025
Current
₹39.63
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹
2025
Current
₹39.63
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹
ALIVUS
ALIVUS
Income
Balance Sheet
Cash Flow
Annual Normal View
ALIVUS Income Statement
ALIVUS Income Statement
Annual Normal View
| Financial Year | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 0.25 | 886.86 | 1,549.30 | 1,885.98 | 2,137.91 | 2,190.18 | 2,295.25 | 2,421.45 | 2,525.46 | |||||||||
Raw Materials | 0.04 | 633.56 | 668.66 | 948.17 | 977.96 | 1,068.56 | 1,025.21 | 1,010.09 | 1,741.00 | |||||||||
| Power & Fuel Cost | 0.00 | 57.81 | 76.75 | 74.19 | 100.92 | 115.60 | 112.46 | 117.24 | ||||||||||
| Employee Cost | 0.15 | 106.28 | 142.28 | 149.13 | 168.72 | 180.18 | 258.16 | 251.70 | ||||||||||
| Selling & Administrative Expenses | 0.00 | 44.20 | 42.05 | 48.50 | 48.64 | 65.47 | 64.12 | 83.58 | ||||||||||
| Operating & Other expenses | 0.08 | -203.15 | 135.61 | 74.11 | 210.91 | 89.11 | 149.02 | 241.69 | ||||||||||
EBITDA | -0.02 | 248.16 | 483.95 | 591.88 | 630.76 | 671.26 | 686.28 | 717.15 | 784.46 | |||||||||
| Depreciation/Amortization | 0.00 | 19.26 | 29.37 | 33.39 | 37.88 | 42.09 | 53.45 | 60.61 | 66.63 | |||||||||
| PBIT | -0.02 | 228.90 | 454.58 | 558.49 | 592.88 | 629.17 | 632.83 | 656.54 | 717.83 | |||||||||
| Interest & Other Items | 0.00 | 0.61 | 33.52 | 87.55 | 27.96 | 0.55 | 1.55 | 2.41 | 4.29 | |||||||||
| PBT | -0.02 | 228.29 | 421.06 | 470.94 | 564.92 | 628.62 | 631.28 | 654.13 | 713.54 | |||||||||
| Taxes & Other Items | 0.42 | 32.71 | 107.97 | 119.37 | 146.20 | 161.65 | 160.40 | 168.50 | 183.18 | |||||||||
| Net Income | -0.44 | 195.58 | 313.09 | 351.57 | 418.72 | 466.97 | 470.88 | 485.63 | 530.36 | |||||||||
| EPS | -8.00 | 36.10 | 29.04 | 32.61 | 36.36 | 38.11 | 38.43 | 39.63 | 43.28 | |||||||||
| DPS | 0.00 | 0.00 | 0.00 | 0.00 | 21.00 | 42.00 | 22.50 | 5.00 | 5.00 | |||||||||
| Payout ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.58 | 1.10 | 0.59 | 0.13 | 0.12 |
ALIVUS Company Updates
FY 2026FY 2026
Investor Presentation
Nov 6PDF
Aug 1PDF
ALIVUS Stock Peers
ALIVUS Past Performance & Peer Comparison
ALIVUS Past Performance & Peer Comparison
Comparing 3 stocks from
Health CarePharmaceuticals
Compare valuation on Screener
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Alivus Life Sciences Ltd | 22.85 | 3.94 | 0.55% |
| Sun Pharmaceutical Industries Ltd | 38.57 | 5.82 | 0.91% |
| Torrent Pharmaceuticals Ltd | 67.85 | 17.08 | 0.84% |
| Cipla Ltd | 23.47 | 3.96 | 1.04% |
ALIVUS Stock Price Comparison
Compare ALIVUS with any stock or ETFCompare ALIVUS with any stock or ETF
ALIVUS
ALIVUS Holdings
ALIVUS Shareholdings
ALIVUS Promoter Holdings Trend
ALIVUS Promoter Holdings Trend
Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
ALIVUS Institutional Holdings Trend
ALIVUS Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
ALIVUS Shareholding Pattern
ALIVUS Shareholding Pattern
ALIVUS Shareholding History
ALIVUS Shareholding History
Foreign Institutions
Mutual Funds Invested in ALIVUS
Mutual Funds Invested in ALIVUS
No mutual funds holding trends are available
Top 5 Mutual Funds holding Alivus Life Sciences Ltd
| Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
The rupee value of the stock held by the fund divided by the stock’s market cap 1.0181% | Percentage of the fund’s portfolio invested in the stock 0.37% | Change in the portfolio weight of the stock over the last 3 months -0.07% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 33/118 (+1) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.8877% | Percentage of the fund’s portfolio invested in the stock 1.43% | Change in the portfolio weight of the stock over the last 3 months -0.17% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 37/65 (0) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.6827% | Percentage of the fund’s portfolio invested in the stock 3.45% | Change in the portfolio weight of the stock over the last 3 months 1.02% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 16/26 (+4) |
Compare 3-month MF holding change on Screener
Hmm, looks like there hasn't been any net deal activity in the last 6 monthssmallcases containing ALIVUS stock
smallcases containing ALIVUS stock
Looks like this stock is not in any smallcase yet.
ALIVUS Events
ALIVUS Events
ALIVUS Dividend Trend
No dividend trend available
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
ALIVUS Dividend Trend
No dividend trend available
ALIVUS Upcoming Dividends
ALIVUS Upcoming Dividends
No upcoming dividends are available
ALIVUS Past Dividends
ALIVUS Past Dividends
Cash Dividend
Ex DateEx DateSep 1, 2025
Final
Final | Div/Share: ₹5.00
Dividend/Share
₹5.00
Ex DateEx Date
Sep 1, 2025
Cash Dividend
Ex DateEx DateOct 17, 2023
Interim
Interim | Div/Share: ₹22.50
Dividend/Share
₹22.50
Ex DateEx Date
Oct 17, 2023
Cash Dividend
Ex DateEx DateMar 24, 2023
Interim
Interim | Div/Share: ₹21.00
Dividend/Share
₹21.00
Ex DateEx Date
Mar 24, 2023
Cash Dividend
Ex DateEx DateSep 15, 2022
Final
Final | Div/Share: ₹10.50
Dividend/Share
₹10.50
Ex DateEx Date
Sep 15, 2022
Cash Dividend
Ex DateEx DateNov 22, 2021
Interim
Interim | Div/Share: ₹10.50
Dividend/Share
₹10.50
Ex DateEx Date
Nov 22, 2021
ALIVUS Stock News & Opinions
ALIVUS Stock News & Opinions
Articles & Videos
Earnings
Alivus Life Sciences standalone net profit rises 36.41% in the September 2025 quarter
Net profit of Alivus Life Sciences rose 36.41% to Rs 130.03 crore in the quarter ended September 2025 as against Rs 95.32 crore during the previous quarter ended September 2024. Sales rose 16.00% to Rs 587.98 crore in the quarter ended September 2025 as against Rs 506.88 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales587.98506.88 16 OPM %30.4726.51 - PBDT192.58142.55 35 PBT174.14127.46 37 NP130.0395.32 36 Powered by Capital Market - Live
1 week agoCapital Market - Live
Corporate
Alivus Life Sciences announces board meeting date
Alivus Life Sciences will hold a meeting of the Board of Directors of the Company on 6 November 2025.Powered by Capital Market - Live
2 weeks agoCapital Market - Live
Corporate
Alivus Life Sciences to conduct AGM
Alivus Life Sciences announced that the Annual General Meeting(AGM) of the company will be held on 8 September 2025.Powered by Capital Market - Live
3 months agoCapital Market - Live
Earnings
Alivus Life Sciences standalone net profit rises 9.02% in the June 2025 quarter
Net profit of Alivus Life Sciences rose 9.02% to Rs 121.54 crore in the quarter ended June 2025 as against Rs 111.48 crore during the previous quarter ended June 2024. Sales rose 2.25% to Rs 601.85 crore in the quarter ended June 2025 as against Rs 588.62 crore during the previous quarter ended June 2024. ParticularsQuarter EndedJun. 2025Jun. 2024% Var. Sales601.85588.62 2 OPM %28.6327.10 - PBDT180.05164.63 9 PBT162.99150.24 8 NP121.54111.48 9 Powered by Capital Market - Live
3 months agoCapital Market - Live
Corporate
Alivus Life Sciences to declare Quarterly Results
Alivus Life Sciences will hold a meeting of the Board of Directors of the Company on 1 August 2025.Powered by Capital Market - Live
3 months agoCapital Market - Live
Corporate
Board of Alivus Life Sciences recommends final dividend
Alivus Life Sciences announced that the Board of Directors of the Company at its meeting held on 15 May 2025, inter alia, have recommended the final dividend of Rs 5 per equity Share (i.e. 250%) , subject to the approval of the shareholders.Powered by Capital Market - Live
6 months agoCapital Market - Live
Earnings
Alivus Life Sciences standalone net profit rises 44.85% in the March 2025 quarter
Net profit of Alivus Life Sciences rose 44.85% to Rs 141.87 crore in the quarter ended March 2025 as against Rs 97.94 crore during the previous quarter ended March 2024. Sales rose 21.05% to Rs 649.55 crore in the quarter ended March 2025 as against Rs 536.60 crore during the previous quarter ended March 2024. For the full year,net profit rose 3.13% to Rs 485.63 crore in the year ended March 2025 as against Rs 470.89 crore during the previous year ended March 2024. Sales rose 4.54% to Rs 2386.88 crore in the year ended March 2025 as against Rs 2283.21 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales649.55536.60 21 2386.882283.21 5 OPM %30.5526.36 -28.6029.53 - PBDT207.27144.21 44 714.74684.74 4 PBT191.30129.68 48 654.13631.29 4 NP141.8797.94 45 485.63470.89 3 Powered by Capital Market - Live
6 months agoCapital Market - Live
Corporate
Alivus Life Sciences to hold board meeting
Alivus Life Sciences will hold a meeting of the Board of Directors of the Company on 15 May 2025.Powered by Capital Market - Live
6 months agoCapital Market - Live
Corporate
Alivus Life Sciences allots 92,096 equity shares under ESOS
Alivus Life Sciences has allotted 92,096 equity shares under ESOS on 30 April 2025. Consequent to the allotment, the paid up equity share capital has increased to 12,26,29,148 equity shares of Rs. 2 each aggregating to Rs. 24,52,58,296/-. Powered by Capital Market - Live
6 months agoCapital Market - Live
Earnings
Alivus Life Sciences standalone net profit rises 15.32% in the December 2024 quarter
Net profit of Alivus Life Sciences rose 15.32% to Rs 136.96 crore in the quarter ended December 2024 as against Rs 118.77 crore during the previous quarter ended December 2023. Sales rose 12.05% to Rs 641.84 crore in the quarter ended December 2024 as against Rs 572.80 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales641.84572.80 12 OPM %29.6530.13 - PBDT200.31173.87 15 PBT185.15160.69 15 NP136.96118.77 15 Powered by Capital Market - Live
9 months agoCapital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of 9.34%, vs industry avg of 10.03%
Over the last 5 years, market share decreased from 0.62% to 0.58%
Over the last 5 years, net income has grown at a yearly rate of 9.18%, vs industry avg of 20.02%